Inovio Pharmaceuticalsの空売り状況は、投資家がInovio Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Inovio Pharmaceuticals (NASDAQ:INO) 株価情報, 空売り情報

Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Innodata Inc

IN OVATIONS HOLDINGS INC by In Ovations Holdings, Inc.

In Ovations Holdings Inc

TPT Strategic Inc

Predictiv AI Inc

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

InfoNow Corp

RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and lowers the price target from $7 to $6.

News

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $6

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Biotech

Large Cap

Eurozone

Health Care

Movers

Trading Ideas

General

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(1.15) by 22.61 percent.

Earnings

Earnings Beats

Inovio Pharmaceuticals Q3 2024 GAAP EPS $(0.89) Beats $(1.15) Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Inovio Pharmaceuticals to report an earnings per share (EPS) of $-1.14.
Investors in Inovio Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.09, leading to a 3.1% drop in the share price the following trading session.
Here's a look at Inovio Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.10</td>
<td>-1</td>
<td>-1.27</td>
<td>-1.56</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.19</td>
<td>-1.31</td>
<td>-1.10</td>
<td>-1.56</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>1.0%</td>
<td>-9.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731513761_0.png" alt="eps graph" />
<h3>Performance of Inovio Pharmaceuticals Shares</h3>
Shares of Inovio Pharmaceuticals were trading at $5.15 as of November 12. Over the last 52-week period, shares are up 4.69%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Inovio Pharmaceuticals</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Inovio Pharmaceuticals.
Analysts have provided Inovio Pharmaceuticals with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $7.0, suggesting a potential 35.92% upside.
<h3>Peer Ratings Comparison</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and Puma Biotechnology, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<h3>Summary of Peers Analysis</h3>
The peer analysis summary presents essential metrics for and Puma Biotechnology, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puma Biotechnology</td>
<td>Buy</td>
<td>-13.72%</td>
<td>$36.42M</td>
<td>-9.10%</td>
</tr>
</tbody>
</table>

Key Takeaway:
In comparison to its peers, Inovio Pharmaceuticals ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas. However, it is in the middle for Return on Equity, suggesting average profitability compared to its peers. Overall, Inovio Pharmaceuticals may need to focus on improving its revenue growth and gross profit to align better with its industry peers.
<h3>Delving into Inovio Pharmaceuticals's Background</h3>
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
<h3>Inovio Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Inovio Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -55.41%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Inovio Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -31993.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Inovio Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -33.72%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -24.52%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Inovio Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/INO/earnings">To track all earnings releases for Inovio Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Inovio Pharmaceuticals's Earnings

<ul>
<li>New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment</li>
<li>New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11</li>
<li>Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK</li>
</ul>
PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. In that prior trial, patients experienced a reduction in surgeries needed to control their RRP caused by HPV-6 and HPV-11. In the recent immunology study, INO-3107 induced the expansion of both existing and new clonal T cells that travel from the blood to the papilloma and airway tissues. The&nbsp;new clonal T cells accounted for the majority of T cells observed in patient papilloma or airway tissue who showed either a complete or partial response to treatment with INO-3107. These new data build upon previously reported evidence that INO-3107 elicits an antigen-specific immune response targeting HPV-6 and HPV-11, to help eliminate or control RRP by reducing the need for surgery.

Immunology Data Shows INOVIO's INO-3107 Induced Expansion Of New Clonal T Cells That Infiltrate Airway Tissue And Correspond With Reduction Of Surgeries For RRP Patients Observed In Phase 1/2 Trial

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

AEMD

CMRX

GOVX

TNXP

VRAX

'UK detects two more cases of new mpox variant' - Reuters

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

APDN

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

INOVIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.
&nbsp;
At AACR's Tumor and Immunology Conference on October 19, INOVIO presented new immunology data demonstrating the ability of INO-3107 to induce antigen-specific T cell responses against HPV-6 and HPV-11 and drive recruitment of those T cells into airway tissues and papilloma of RRP patients, which could ultimately slow or eliminate papilloma regrowth. Additionally, INOVIO will tomorrow present its full safety and efficacy data set for the Phase 1/2 trial for INO-3107 at the International Society of Vaccines Conference. In the trial, INO-3107 was found to be well tolerated and immunogenic. Of the 32 patients in the trial, 26 patients, or 81%, experienced a decrease in the number of surgical interventions in the year after treatment when compared to the year before treatment.
"The new immunology data support the proposed mechanism of action of INO-3107 which is to generate an immune response that can seek out and eliminate HPV-6 and HPV-11 infected cells that are the underlying cause of papilloma growth," said Dr. Matthew Morrow, INOVIO's Vice President of Translational Science.&nbsp;"Our analysis shows that INO-3107 induced significant clonal T cell expansion in the blood, including antigen-specific killer T cells. Investigators also observed T cell infiltration into airway tissue, which is positively associated with clinical response."
"The collective story these data sets provide is compelling. Over 81% of patients who received INO-3107 required fewer surgical procedures compared to baseline, a result that is further supported by the new immunology data demonstrating the ability of INO-3107 to stimulate the immune system and generate antigen-specific T cells that travel to the airways and could eliminate the underlying disease," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We believe these data continue to demonstrate that INO-3107 has the potential to significantly improve the lives of patients living with RRP and become the preferred choice for the broadest number of RRP patients and healthcare providers."

INOVIO Presents Data on INO-3107's Immune Response Against HPV-6 and HPV-11

4 analysts have shared their evaluations of Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Inovio Pharmaceuticals, presenting an average target of $15.75, a high estimate of $33.00, and a low estimate of $7.00. Highlighting a 14.86% decrease, the current average has fallen from the previous average price target of $18.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1728072169_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Inovio Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inovio Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Inovio Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Inovio Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Inovio Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Inovio Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Inovio Pharmaceuticals's Background</h2>
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
<h3>Key Indicators: Inovio Pharmaceuticals's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Inovio Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -55.41%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Inovio Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -31993.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Inovio Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -33.72%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Inovio Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -24.52%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Inovio Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts

RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and lowers the price target from $8 to $7.

RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $7

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

-Reuters Citing Senior Administration Official

President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Global

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

US To Stay Committed In Bringing Mpox Outbreak Under Control

Morocco Records First Case Of Mpox

CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels

<a href="https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926">https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926</a>
&nbsp;
Senior Biden administration officials said Friday that the United States is preparing for the possible arrival of <a href="https://www.nbcnews.com/health/health-news/mpox-strain-spreads-cdc-who-stronger-warnings-rcna165155">a more severe version of mpox</a>, which has taken off in the Democratic Republic of Congo and other countries in Africa resulting in more than 600 deaths there.
As of Thursday, there have been more than 24,800 reported cases of this version of the virus, <a href="https://www.nbcnews.com/health/health-news/mpox-virus-outbreak-symptoms-2024-spread-rcna166778">known as clade 1</a>, so far this year, the World Health Organization said at a separate briefing Friday.&nbsp;The WHO declared the outbreak a<a href="https://www.nbcnews.com/health/health-news/who-declares-mpox-global-public-health-emergency-second-time-rcna166601"> global health emergency</a> in August.
Last month,<a href="https://www.nbcnews.com/health/health-news/sweden-confirms-first-case-mpox-strain-congo-rcna166763"> Sweden confirmed a case of clade 1</a>, the first known case outside of Africa, followed by a case in Thailand several days later. Both patients had spent time in Africa.
A different version of mpox, clade 2, triggered a global outbreak in 2022 and a surge of cases in the U.S. Clade 1 is more severe and can kill up to 10% of people infected, though recent death rates have been around 1% to 3.3%, <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">according to the CDC.</a>
On a call with reporters, senior administration officials said that as infections have risen in Africa, the U.S. has been gearing up for its own cases.&nbsp;
"We've been preparing for the arrival of clade 1 in the United States for many months now, especially as we saw the outbreak in DRC and neighboring countries accelerate," one official said.
The government is expanding its mpox surveillance efforts, primarily through wastewater analysis, and is reaching out to the medical community to educate members on what to watch for, including the severity of clade 1 and how it spreads, according to officials.
Officials said they're also making sure testing is more widely available.
Any doctor in the U.S. can order an mpox test that can be run through a national laboratory. If positive, it can be tested for clade 2. If those results are negative for clade 2, the doctor can make a presumptive diagnosis of clade 1; that diagnosis will need to be officially confirmed by the Centers for Disease Control and Prevention, according to officials.
The Jynneos mpox vaccine, given in two doses, is effective against both clade 1 and clade 2 of mpox.
The CDC's vaccine recommendation remains limited to anyone who is considered at high risk of catching the virus, mainly gay and bisexual men.&nbsp;
Most people with health insurance can get the vaccine at major pharmacy retail chains including CVS and Walgreens, the officials said. The vaccine is also available for free at public health departments and community health centers.
More vaccines are being held in the U.S. national stockpile, officials said, although they declined to say how many.&nbsp;
"There is a sufficient amount of vaccine for the U.S. population," an official said.&nbsp;
The U.S. is also working with government scientists and drug companies to develop potential new treatments. There are currently no approved treatments for mpox. The Food and Drug Administration has approved an antiviral treatment known as TPOXX for smallpox, which is closely related to mpox, although a recent clinical trial found that the drug is <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo">not effective against clade 1</a>.&nbsp;

'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC

Warning: INO is at high risk of performing badly

This week, several major companies will be reporting earnings. Among them are Alibaba (BABA), Walt Disney (DIS), Plug Power (PLUG), Cisco Systems (...

Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024

Inovio Pharmaceuticals Q3 2024 Earnings Preview

Here are the major earnings after the close today

Inovio Pharmaceuticals Non-GAAP EPS of -$0.89 beats by $0.24

"We continue to be focused on advancing INO-3107 and delivering a non-surgical option to RRP patients. Toward this goal, we expect to have all non-...

Inovio reports Q3 EPS (89c), consensus ($1.13)

Inovio Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS –&nbsp; Gain Therapeutics&nbsp;...

Closing Bell Movers: Applied Materials down 6% after earnings, guidance

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with a p...

RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)

BABA

BNGO

CRON

CSCO

GANX

GOEV

HOOK

LAZR

LNVGY

MARA

NVAX

PLUG

POOL

PPSI

PSTV

REKR

RKLB

RSLS

SHOP

SOUN

SPOT

SPRO

SRFM

STNE

SWKS

TTOO

VUZI

VXRT

WKHS

Press Releases

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

INOVIO to Present at Upcoming Scientific Conference

INOVIO to Present at Upcoming Scientific Conferences

INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Comments

Inovio Pharmaceuticals

空売り

Inovio Pharmaceuticals (NASDAQ:INO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル